Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV

Vaccine

Volumn 30, Issue 3, 2012, Pages 607-613

  Ali Tabei, S M ^a   Li, Ying ^a,b   Weigert, Martin ^b,c   Dinner, Aaron R ^a,b,d  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

Broadly neutralizing antibodies; HIV; Mathematical model; Passive immunization; Self epitopes

Indexed keywords

ANTIRETROVIRUS AGENT; BROADLY NEUTRALIZING ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IN VIVO STUDY; INFLUENZA; MATHEMATICAL MODEL; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; VIRUS LOAD;

ANTIBODIES, NEUTRALIZING; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNIZATION, PASSIVE; MODELS, THEORETICAL; VIRAL LOAD;

EID: 84355161381     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.048     Document Type: Article

References (25)

1. Fauci A.S., Dieffenbach C.W., Burton D.R., Hammer S.M., Hoxie J.A., Martin M., et al. HIV vaccine research: the way forward. Science 2008, 321:530-532.
2. Karlsson Hedestam G.B., Fouchier R.A., Phogat S., Burton D.R., Sodroski J., Wyatt R.T. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008, 6:143-155.
3. Trkola A., Kuster H., Rusert P., Joos B., Fischer M., Leemann C., et al. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005, 11:615-622.
4. Haynes B.F., Fleming J., St Clair E.W., Katinger H., Stiegler G., Kunert R., et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908.
5. Mascola J.R., Lewis M.G., Stiegler G., Harris D., VanCott T.C., Hayes D., et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999, 73:4009-4018.
6. Mascola J.R., Stiegler G., VanCott T.C., Katinger H., Carpenter C.B., Hanson C.E., et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000, 6:207-210.
7. Zhang L., Ribeiro R.M., Mascola J.R., Lewis M.G., Stiegler G., Katinger H., et al. Effects of antibody on viral kinetics in simian/human immunodeficiency virus infection: implications for vaccination. J Virol 2004, 78:5520-5522.
8. Manrique A., Rusert P., Joos B., Fischer M., Kuster H., Leemann C., et al. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 2007, 81:8793-8808.
9. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 2009, 16:265-273.
10. Deguchi H., Fernandez J.A., Hackeng T.M., Banka C.L., Griffin J.H. Cardiolipin is a normal component of human plasma lipoproteins. Proc Natl Acad Sci U S A 2000, 97:1743-1748.
11. Callaway D.S., Perelson A.S. HIV-1 infection and low steady state viral loads. Bull Math Biol 2002, 64:29-64.
12. Davenport M.P., Ribeiro R.M., Zhang L., Wilson D.P., Perelson A.S. Understanding the mechanisms and limitations of immune control of HIV. Immunol Rev 2007, 216:164-175.
13. Wodarz D., Nowak M.A. Mathematical models of HIV pathogenesis and treatment. Bioessays 2002, 24:1178-1187.
14. Nowak M.A., May R.M.C. Virus dynamics: mathematical principles of immunology and virology 2000, Oxford University Press, Oxford.
15. Ciupe S.M., Bivort B.L., Bortz D.M., Nelson P.W. Estimating kinetic parameters from HIV primary infection data through the eyes of three different mathematical models. Math Biosci 2006, 200:1-27.
16. Alam S.M., Mc Adams M., Boren D., Rak M., Scearce R.M., Gao F., et al. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J Immunol 2007, 178:4424-4435.
17. Armbruster C., Stiegler G.M., Vcelar B.A., Jäger W., Köller U., Jilch R., et al. Passive immunization with the anti-HIV-1 human monoclonal antibody (hMAb) 4E10 and the hMAb combination 4E10/2F5/2G12. J Antimicrob Chemother 2004, 54:915-920.
18. Ciupe S.M., De Leenheer P., Kepler T.B. Paradoxical suppression of poly-specific broadly neutralizing antibodies in the presence of strain-specific neutralizing antibodies following HIV infection. J Theor Biol 2011, 277:55-66.
19. Verkoczy L., Diaz M., Holl T.M., Ouyang Y.B., Bouton-Verville H., Alam S.M., et al. Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance. Proc Natl Acad Sci U S A 2010, 107:181-186.
20. Oprea M., Perelson A.S. Exploring the mechanism of primary antibody responses to T-cell-dependent antigen. J Theor Biol 1996, 181:215-236.
21. Sigounas G., Harindranath N., Notkins A.L. Half-life of polyreactive antibodies. J Clin Immunol 1994, 14:134-140.
22. Sigounas G., Kolaitis N., Monell-Torrens E., Notkins A.L., Polyreactive IgM antibodies in the circulation are masked by antigen binding. J Clin Immunol 1994, 14:375-381.
23. Walker L.M., Phogat S.K., Chan-Hui P.Y., Wagner D., Phung P., Goss J.L., et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289.
24. Wu X., Yang Z.Y., Li Y., Hogerkorp C.M., Schief W.R., Seaman M.S., et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329:856-861.
25. Baccam P., Beauchemin C., Macken C.A., Hayden F.G., Perelson A.S. Kinetics of influenza A virus infection in humans. J Virol 2006, 80:7590-7599.